HIF-1-Independent Mechanisms Regulating Metabolic Adaptation in Hypoxic Cancer Cells
Open accessThe DOI matches its Crossref record; 215 of the 219 references it cites were found in a registry or an index; 87 of the 126 sources its claims cite were checked for support.
Abstract
In solid tumours, cancer cells exist within hypoxic microenvironments, and their metabolic adaptation to this hypoxia is driven by HIF-1 transcription factor, which is overexpressed in a broad range of human cancers. HIF inhibitors are under pre-clinical investigation and clinical trials, but there is evidence that hypoxic cancer cells can adapt metabolically to HIF-1 inhibition, which would provide a potential route for drug resistance. Here, we review accumulating evidence of such adaptions in carbohydrate and creatine metabolism and other HIF-1-independent mechanisms that might allow cancers to survive hypoxia despite anti-HIF-1 therapy...
Overview
CoChat Summary
TL;DR
This review argues that hypoxic cancer cells can maintain metabolism and survive even when HIF-1 is inhibited, using compensatory mechanisms in glucose, glutamine, lipid, and creatine metabolism plus epigenetic and signaling pathways. The authors conclude that targeting HIF-1 alone is unlikely to be enough and that combination strategies will probably be needed.
Key findings
- In HIF-1/2-deficient Hepa-1 c4 tumors, glycolysis still adapted to hypoxia: glucose uptake was unchanged by FDG-PET, ATP was about 20% of Hepa WT levels, and c4 tumors had a 4.5-fold higher AMP/ATP ratio with higher PFK-1 activity.
- In HIF-1α knockout HCT116 colorectal cancer cells, glucose uptake was maintained by GLUT14 regulated by HIF-2α, and creatine metabolism became important for survival; inhibition of creatine kinase B (CKB) reduced clonogenic potential and 3D spheroid growth under hypoxia.
- In Myc-overexpressing small cell lung cancer cells lacking HIF-1α, glutamine was critical and sufficient for ATP production: blocking glutaminase caused cell death, while glucose withdrawal did not affect viability.
- The review highlights multiple HIF-independent adaptation routes, including epigenetic reprogramming, post-translational SUMOylation, spatial clustering of glycolytic enzymes (“G bodies”), PI3K-Akt-mTOR, 2-hydroxyglutarate, and AMPK/PGC-1α signaling.
Methods
- Narrative review of prior studies on hypoxic cancer-cell metabolism, with emphasis on HIF-1-independent adaptation and resistance to anti-HIF therapy.
- Synthesizes evidence from multi-omics studies (transcriptomic, proteomic, metabolomic), genetic knockouts/knockdowns, pharmacologic inhibition, and hypoxic cell/tumor models.
- Main analysis is qualitative: comparison and integration of reported findings across cancer models, rather than a new experimental dataset or meta-analysis.
Limitations
- The paper does not report a systematic review protocol, formal search strategy, or quantitative synthesis; this is evident from the text.
- The authors explicitly note uncertainty in several areas, such as the exact mechanisms linking AMPK, 2-HG, PGC-1α, and hypoxia, and say that many findings “remain unknown” or “need further clarification.”
- The evidence base is heterogeneous and often model-specific; this is evident from the text, which repeatedly contrasts Hepa c4, HCT116, SCLC, and other systems, some with intact HIF-2 signaling and some without.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
57 Valid · 5 Not valid · 16 Not checked · 16 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“There was an accumulation of glycolytic intermediates, with a block of conversion of fructose-1,6-bisphosphate (Fru-1,6-BP) to dihydroxyacetone phosphate (DHAP) at the level of aldolase [58] rather than the earlier step of conversion of fructose-6-phosphate (Fru-6P) to Fru-1,6BP by PFK observed in c4 cells and tumors [16].”
§ HIF-1-Independent Mechanisms Regulating Metabolic Adaptation in Hypoxic Cancer Cells > 4. Glucose Metabolism in Cancer Cells in Deficient in HIF-1 under Hypoxia > 4.2. Auxiliary Functions of Glucose Uptake & Creatine Metabolism in Hypoxia
What the sources say
- Not checked — no full text of the sourcecites [58] Valli, 2019, Adaptation to HIF1a deletion in hypoxic cancer cells by upregulation of GLUT14 and creatine metabolism, Mol. Cancer Res. source
- Disputedcites [16] Golinska, M., Troy, H., Chung, Y.L., McSheehy, P.M., Mayr, M., Yin, X., Ly, L., Williams, K.J., Airley, R.E., and Harris, A.L. (2011). Adaptation to HIF-1 deficiency by upregulation of the AMP/ATP ratio and phosphofructokinase activation in hepatomas. BMC Cancer, 11. sourceExperimental — accuracy not yet measured
The citation to this paper attaches to the proposed PFK block in c4 cells and tumours, not to the aldolase finding attributed to Valli et al. The Discussion (page unavailable) says instead that PFK-1 activity was higher in c4 cells at their prevailing ATP/AMP ratio and that c4 tumours maintained a normal rate of glycolysis. (LLM, conf=0.89)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Several preclinical models of HIF-1-deficient tumours initially undergo a period of slow growth before subsequently demonstrating accelerated growth, suggesting the development of resistance and escape mechanisms from the inhibition of HIF-1 [13,14,15,16].”
§ HIF-1-Independent Mechanisms Regulating Metabolic Adaptation in Hypoxic Cancer Cells > 1. Introduction
What the sources say
- Partly supportedcites [13] Maxwell, 1997, Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth, Proc. Natl. Acad. Sci. USA sourceExperimental — accuracy not yet measured
The Results (Differences in Xenograft Growth; page unavailable) report that HIF-1-deficient c4 xenografts generally grew more slowly, with occasional faster-growing exceptions. The Discussion suggests possible escape mechanisms, but does not show that individual tumours first grew slowly and then accelerated, or establish this pattern across several preclinical models. (LLM, conf=0.86)
- Not checked — no full text of the sourcecites [14] Williams, 2002, A protective role for HIF-1 in response to redox manipulation and glucose deprivation: Implications for tumorigenesis, Oncogene source
- Not checked yetcites [15] Griffiths, 2002, Metabolic changes detected by in vivo magnetic resonance studies of HEPA-1 wild-type tumors and tumors deficient in hypoxia-inducible factor-1beta (HIF-1beta): Evidence of an anabolic role for the HIF-1 pathway, Cancer Res.
- Supportedcites [16] Golinska, M., Troy, H., Chung, Y.L., McSheehy, P.M., Mayr, M., Yin, X., Ly, L., Williams, K.J., Airley, R.E., and Harris, A.L. (2011). Adaptation to HIF-1 deficiency by upregulation of the AMP/ATP ratio and phosphofructokinase activation in hepatomas. BMC Cancer, 11. source
The Background states that in many cases HIF-1-deficient tumours accelerate after a period of slow growth and describes this as escape from impaired HIF-1 function. The Results and Discussion also report an initial growth delay followed by escape in the paper’s c4 tumour model. Page numbers are not available in the supplied copy. (LLM, conf=0.91)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Although in normal cells HIF-1 signalling occupies a central role in orchestrating the adaptive response of glycolysis to hypoxia, loss of HIF-1 in cancer cells and solid tumours paradoxically does not perturb the glycolytic phenotype [15,16,29].”
§ HIF-1-Independent Mechanisms Regulating Metabolic Adaptation in Hypoxic Cancer Cells > 2. Glucose Metabolism & Hypoxia To begin, we will briefly introduce the basic steps of glucose metabolism and examine how it changes under hypoxia. Glycolysis converts a single molecule of glucose into two molecules of pyruvate, with the net phosphorylation of 2 molecules of adenosine diphosphate (ADP) to adenosine triphosphate (ATP) and reduction of 2 molecules of nicotinamide adenosine dinucleotide (NAD) to NADH (reduced NAD) [1]. The fate of pyruvate is variable: it can be converted to lactate or carbon dioxide, depending on the availability of oxygen. In the presence of sufficient levels of oxygen, pyruvate is further oxidised by the tricarboxylic acid cycle (TCA) in the mitochondria, generating electron carriers to the electron transport chain which generate a further 36 molecules of ATP per molecule of glucose entering the glycolytic pathway [1]. In hypoxia, pyruvate remains within the cytoplasm and is converted to lactate in a reaction catalysed by lactate dehydrogenase [1]. This allows for the regeneration of NAD+ from NADH to maintain glycolysis during hypoxia [1]. High rates of glycolysis allow glycolytic intermediates to be channelled towards one-carbon metabolism to produce NADPH (reduced nicotinamide adenine dinucleotide phosphate) and nucleotides, enabling rapid biosynthesis for growth and proliferation [17]. This mechanism has been postulated to account for the Warburg effect, or aerobic glycolysis, by which proliferating cancer cells metabolise glucose via glycolysis even in the presence of oxygen [17,18]. The rate of glycolysis depends not only on the availability and uptake of glucose, but also on the kinetics of the metabolic enzymes that catalyse several rate-limiting steps along the pathway. Among these enzymes, hexokinase (HK), phosphofructokinase (PFK), and pyruvate kinase (PK) are allosterically regulated and have important roles in regulating glycolytic flux [19,20,21,22]. The initial switch that upregulates glycolysis in hypoxia has been traditionally attributed to the allosteric control of glycolytic enzymes by ATP [23]. This is followed by an important longer-term adaptive mechanism through HIF-1-dependent upregulation of the synthesis of glucose transporters and glycolytic enzymes [24,25,26,27]. This adaptive mechanism, which promotes survival of normal cells during hypoxia, is frequently hijacked by cancer cells, which then respire by aerobic glycolysis—the Warburg effect [18,28].
What the sources say
- Not checked yetcites [15] Griffiths, 2002, Metabolic changes detected by in vivo magnetic resonance studies of HEPA-1 wild-type tumors and tumors deficient in hypoxia-inducible factor-1beta (HIF-1beta): Evidence of an anabolic role for the HIF-1 pathway, Cancer Res.
- Partly supportedcites [16] Golinska, M., Troy, H., Chung, Y.L., McSheehy, P.M., Mayr, M., Yin, X., Ly, L., Williams, K.J., Airley, R.E., and Harris, A.L. (2011). Adaptation to HIF-1 deficiency by upregulation of the AMP/ATP ratio and phosphofructokinase activation in hepatomas. BMC Cancer, 11. sourceExperimental — accuracy not yet measured
The Conclusions (page unavailable) state that HIF-1-deficient c4 hepatoma tumours perform glycolysis at the normal rate despite reduced amounts of most glycolytic enzymes. This supports preserved glycolytic flux in that model, but not an unqualified claim about cancer cells and solid tumours generally; the enzyme changes also mean the glycolytic phenotype was not wholly unperturbed. (LLM, conf=0.86)
- Not checked — no full text of the sourcecites [29] Troy, 2005, Metabolic profiling of hypoxia-inducible factor-1β-deficient and wild type Hepa-1 cells: Effects of hypoxia measured by 1H magnetic resonance spectroscopy, Metabolomics source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“The cell membrane creatinine transporter SLC6A8 was found to be upregulated by hypoxia equally in both wild type and HIF-1α knockout HCT116 cells [54].”
§ HIF-1-Independent Mechanisms Regulating Metabolic Adaptation in Hypoxic Cancer Cells > 4. Glucose Metabolism in Cancer Cells in Deficient in HIF-1 under Hypoxia > 4.2. Auxiliary Functions of Glucose Uptake & Creatine Metabolism in Hypoxia
What the sources say
- Could not verifycites [54] Wise, 2011, Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of α-ketoglutarate to citrate to support cell growth and viability, Proc. Natl. Acad. Sci. USA sourceExperimental — accuracy not yet measured
The Results and Materials and Methods passages describe hypoxia experiments in SF188 and RCC4 cells, not HCT116 cells. Searches for SLC6A8 and for the claimed transporter comparison found no passage in our copy addressing its expression in wild-type versus HIF-1α-knockout HCT116 cells. No page numbers were provided. (LLM, conf=0.76)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Despite lacking functional HIF-1/2 pathways, Hepa c4 cells were able to upregulate glycolysis to the same extent as their wild type (Hepa WT) counterparts when cultured under hypoxia [15,16,29].”
§ HIF-1-Independent Mechanisms Regulating Metabolic Adaptation in Hypoxic Cancer Cells > 4. Glucose Metabolism in Cancer Cells in Deficient in HIF-1 under Hypoxia > 4.1. Allosteric Regulation of Glycolytic Enzymes under Hypoxia
What the sources say
- Not checked — no full text of the sourcecites [15] Griffiths, 2002, Metabolic changes detected by in vivo magnetic resonance studies of HEPA-1 wild-type tumors and tumors deficient in hypoxia-inducible factor-1beta (HIF-1beta): Evidence of an anabolic role for the HIF-1 pathway, Cancer Res.
- Supportedcites [16] Golinska, M., Troy, H., Chung, Y.L., McSheehy, P.M., Mayr, M., Yin, X., Ly, L., Williams, K.J., Airley, R.E., and Harris, A.L. (2011). Adaptation to HIF-1 deficiency by upregulation of the AMP/ATP ratio and phosphofructokinase activation in hepatomas. BMC Cancer, 11. source
The Background says c4 cells lacking a functioning HIF-1 pathway activated glycolysis under hypoxia to the same extent as WT cells. The Discussion adds that absent nuclear HIF-1β rules out HIF-2α pathways and reports comparable lactate output, an indicator of glycolytic flux, in hypoxic c4 and WT cultures. (LLM, conf=0.94)
- Not checked — no full text of the sourcecites [29] Troy, 2005, Metabolic profiling of hypoxia-inducible factor-1β-deficient and wild type Hepa-1 cells: Effects of hypoxia measured by 1H magnetic resonance spectroscopy, Metabolomics source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
40 more claims · 19 with their cited sources checked
Create a free account to see all 94 claims and to verify the 5 references still open.
- Probably not a substantial claim. 9
- It may state two separate claims as one. 44
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Self-check results appear here once an independent check has confirmed them.
Cited works that were retracted
Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.
A note, not an issue: for example, a cited work that was retracted only after this paper was published, which its authors could not have known.
In the paper
“Zhang, 2008, Mitochondrial Autophagy Is an HIF-1-dependent Adaptive Metabolic Response to Hypoxia, J. Biol. Chem., 283, 10892, 10.1074/jbc.M800102200”
Cited work 10.1074/jbc.m800102200 · retracted 2023-08-07 · notice 10.1016/j.jbc.2023.105125 · this paper published 2021-09-09
Citations
Cites
1 retracted
Mitochondrial Autophagy Is an HIF-1-dependent Adaptive Metabolic Response to Hypoxia
Zhang, H., Bosch-Marce, M., Shimoda, L. A., Tan, Y. S., Baek, J. H., Wesley, J. B., Gonzalez, F. J., & Semenza, G. L. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m800102200 · Cited by 1,601
RetractedUnderstanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009) · Science · doi:10.1126/science.1160809 · Cited by 16,197
Wang, G. L., Jiang, B. H., Rue, E. A., & Semenza, G. L. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.12.5510 · Cited by 6,212
Jaakkola, P., Mole, D. R., Tian, Y.-M., Wilson, M. I., Gielbert, J., Gaskell, S. J., Kriegsheim, A. V., Hebestreit, H. F., Mukherji, M., Schofield, C. J., et al. (2001) · Science · doi:10.1126/science.1059796 · Cited by 5,535
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180
The Warburg Effect: How Does it Benefit Cancer Cells?
Liberti, M. V., & Locasale, J. W. (2016) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2015.12.001 · Cited by 5,150
HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O 2 Sensing
Ivan, M., Kondo, K., Yang, H., Kim, W., Valiando, J., Ohh, M., Salic, A., Asara, J. M., Lane, W. S., & Kaelin Jr., W. G. (2001) · Science · doi:10.1126/science.1059817 · Cited by 4,735
Mutational landscape and significance across 12 major cancer types
Kandoth, C., McLellan, M. D., Vandin, F., Ye, K., Niu, B., Lu, C., Xie, M., Zhang, Q., McMichael, J. F., Wyczalkowski, M. A., et al. (2013) · Nature · doi:10.1038/nature12634 · Cited by 4,419
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154
The Biology of Cancer: Metabolic Reprogramming Fuels Cell Growth and Proliferation
DeBerardinis, R. J., Lum, J. J., Hatzivassiliou, G., & Thompson, C. B. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2007.10.002 · Cited by 4,088
Cited by
Tumor glycolysis, an essential sweet tooth of tumor cells
Paul, S., Ghosh, S., & Kumar, S. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.09.007 · Cited by 449
Targeting the tumor microenvironment: Potential strategy for cancer therapeutics
Babar, Q., Saeed, A., Tabish, T. A., Sarwar, M., & Thorat, N. D. (2023) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2023.166746 · Cited by 125
Hypoxia-inducible factor in breast cancer: role and target for breast cancer treatment
Zhi, S., Chen, C., Huang, H., Zhang, Z., Zeng, F., & Zhang, S. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1370800 · Cited by 105
Chang, Y., Chan, M., Yang, Y., Li, C., & Hsiao, M. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216179 · Cited by 83
The Role of Hypoxia-Inducible Factor-1 Alpha in Renal Disease
Liu, H., Li, Y., & Xiong, J. (2022) · Molecules · doi:10.3390/molecules27217318 · Cited by 83
Akinsipe, T., Mohamedelhassan, R., Akinpelu, A., Pondugula, S. R., Mistriotis, P., Avila, L. A., & Suryawanshi, A. S. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1302587 · Cited by 87
Glutathione-Dependent Pathways in Cancer Cells
Kalinina, E. V. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25158423 · Cited by 88
“In melanoma, the upregulation of GPx3 plays a role in regulating ROS levels by inhibiting the expression of HIF1 α [131,132], which is upregulated in various human cancers and plays a key role in driving tumor growth, invasion, and metastasis.”
BackgroundHypoxia: syndicating triple negative breast cancer against various therapeutic regimens
Srivastava, N., Usmani, S. S., Subbarayan, R., Saini, R., & Pandey, P. K. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1199105 · Cited by 72
Lathigara, D., Kaushal, D., & Wilson, R. B. (2023) · Metabolites · doi:10.3390/metabo13050675 · Cited by 68
“Cytoplasmic glycolysis and the production of lactate from pyruvate occur in some rapidly proliferating cancer cells even in the presence of oxygen, and is termed the Warburg effect or aerobic glycolysis [123,124].”
BackgroundInfluentialNi, X., Lu, C., Xu, G.-Q., & Ma, J. (2024) · Acta Pharmacologica Sinica · doi:10.1038/s41401-024-01264-1 · Cited by 71
“For example, hypoxia-inducible factor-1 (HIF-1) as the most common transcriptional factor upregulates glycolytic proteins, resulting in the increased glycolytic fl ux and eventually maintaining cellular ATP production under hypoxia [10].”
Resistance of Lenvatinib in Hepatocellular Carcinoma
Xu, Q., Huang, D., Guo, J., & Zhao, J. (2022) · Current Cancer Drug Targets · doi:10.2174/1568009622666220428111327 · Cited by 61
Ferini, G., Castorina, P., Valenti, V., Illari, S. I., Sachpazidis, I., Castorina, L., Marrale, M., & Pergolizzi, S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.809279 · Cited by 51
Xiang, J., Deng, Y., Liu, H., & Pu, Y. D. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.858558 · Cited by 54
Temre, M. K., Kumar, A., & Singh, S. M. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1035510 · Cited by 45
“The metabolic switching of cancer cells is mainly attributed to HIF and its downstream signaling pathways (Semenza, 2010; Zhao T et al., 2014; Masoud and Li, 2015; Nagao et al., 2019; Lee et al., 2021).”
BackgroundZheng, Y., Li, L., Shen, Z., Wang, L., Niu, X., Wei, Y., Sun, S., & Zhao, J. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03202-9 · Cited by 52
“This accumulation initiates the transcription of genes encoding glucose transporters and glycolytic enzymes, thereby elevating glycolytic flux [24].”
BackgroundThe Impact of Metabolic Rewiring in Glioblastoma: The Immune Landscape and Therapeutic Strategies
Vijayanathan, Y., & Ho, I. A. W. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26020669 · Cited by 52
“Unfortunately, GBM cells can adapt to HIF1 α inhibition by utilizing alternate metabolic pathways, such as creatine metabolism and GLUT14-mediated glucose uptake [43].”
Li, J., Shang, L., Zhou, F., Wang, S., Liu, N., Zhou, M., Lin, Q., Zhang, M., Cai, Y., Chen, G., et al. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115690 · Cited by 40
Ascorbate Is a Primary Antioxidant in Mammals
Fujii, J., Osaki, T., & Bo, T. (2022) · Molecules · doi:10.3390/molecules27196187 · Cited by 48
Insight into the Effects of High‐Altitude Hypoxic Exposure on Learning and Memory
Zhang, Z.-A., Sun, Y., Yuan, Z., Wang, L., Dong, Q., Zhou, Y., Zheng, G., Aschner, M., Zou, Y., & Luo, W. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/4163188 · Cited by 42
“HIF promotes the expression of glycolysis-related enzymes by reducing cell division and inhibits the phosphorylation of pyruvate dehydrogenase (PDH) to mediate the conversion of the body ’ s metabolic pathways from oxidative phosphorylation to glycolysis and improve adaption to hypoxia [19, 32, 33].”
Tumor energy metabolism: implications for therapeutic targets
Hu, Y., Liu, W., Fang, W., Dong, Y., Zhang, H., & Luo, Q. (2024) · Molecular Biomedicine · doi:10.1186/s43556-024-00229-4 · Cited by 40
Huang, F., Gao, T., Feng, Y., Xie, Y., Tai, C., Huang, Y., Li, L., & Wang, B. (2024) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.4c08174 · Cited by 34
Cao, M., Zhao, X., Xia, F., Shi, M., Zhao, D., Li, L., & Jiang, H. (2025) · Frontiers in Physiology · doi:10.3389/fphys.2025.1623500 · Cited by 35
Moniz, I., Ramalho‐Santos, J., & Branco, A. F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073749 · Cited by 28
“The hypoxia-inducible factor 1 (HIF-1) complex has emerged as one of the main components of hypoxia response in most cell lines [5,6].”
BackgroundCellular Adaptation Takes Advantage of Atavistic Regression Programs during Carcinogenesis
Gnocchi, D., Nikolić, D., Paparella, R. R., Sabbà, C., & Mazzocca, A. (2023) · Cancers · doi:10.3390/cancers15153942 · Cited by 30
“Existing evidence suggests that targeting HIF-1α is not sufficient to disrupt the metabolism of cancer cells [47], which highlights the need for further investigation of anti-HIF-1 drugs, including their combination with other therapeutic approaches [137].”
BackgroundThe Significance of Microenvironmental and Circulating Lactate in Breast Cancer
Frisardi, V., Canovi, S., Vaccaro, S., & Frazzi, R. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242015369 · Cited by 28
“HIF-1 α regulates many pivotal pathways in normal as well as cancerous cells, including angiogenesis, cell proliferation, survival, and tumor progression, through the regulation of growth promoters, oncogenes, glycolytic pathways, and pH [78,79].”
BackgroundMicroRNAs-mediated regulation of glucose transporter (GLUT) expression in glioblastoma
Beylerli, O., Суфианова, Г. З., Shumadalova, A. V., Zhang, D., & Фанилевич, Г. И. (2022) · Non-coding RNA Research · doi:10.1016/j.ncrna.2022.09.001 · Cited by 26
Targeting hypoxic and acidic tumor microenvironment by nanoparticles: A review
Saadh, M. J., Mustafa, M. A., Qassem, L. Y., Ghadir, G. K., Alaraj, M., Alubiady, M. H. S., Al‐Abdeen, S. H. Z., Shakier, H. G., Alshahrani, M. Y., & Zwamel, A. H. (2024) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2024.105660 · Cited by 33
Ahuja, S., Sureka, N., & Zaheer, S. (2024) · Apmis · doi:10.1111/apm.13447 · Cited by 30
“Under hypoxic conditions, HIF-1 a translocates to the nucleus to form a heterodimer with HIF-1 b which in turn upregulates the expression of hypoxia-responsive genes like hexokinase-2, phosphofructokinase-1, aldolase A, pyruvate kinase, lactate dehydrogenase, and phosphoglycerate kinase-1 (85).”
Role of Ischemia/Reperfusion and Oxidative Stress in Shock State
Vázquez-Galán, Y. I., Guzmán-Silahua, S., Trujillo-Rangel, W. Á., & Rodríguez-Lara, S. Q. (2025) · Cells · doi:10.3390/cells14110808 · Cited by 33
Cai, S., Fan, X., Wu, J., Wang, Y., Hu, X., Pei, S., Zheng, Y., Chen, J., Huang, Y., Li, N., et al. (2023) · Acta Pharmacologica Sinica · doi:10.1038/s41401-022-01037-8 · Cited by 26
Oxidative stress-mediated epigenetic remodeling, metastatic progression and cell signaling in cancer
Phull, A. R., Arain, S. Q., Majid, A., Fatima, H., Ahmed, M., & Kim, S. J. (2024) · ONCOLOGIE · doi:10.1515/oncologie-2024-0157 · Cited by 28
The putative role of ferroptosis in gastric cancer: a review
Wang, L., & Wang, H. (2023) · European Journal of Cancer Prevention · doi:10.1097/cej.0000000000000817 · Cited by 30
How to enhance MSCs therapeutic properties? An insight on potentiation methods
García-Guerrero, C., Fuentes, P., Araya, M. J., Djouad, F., Luz‐Crawford, P., Vega-Letter, A. M., & Altamirano, C. (2024) · Stem Cell Research & Therapy · doi:10.1186/s13287-024-03935-6 · Cited by 25
Gaebler, D., Hachey, S. J., & Hughes, C. C. W. (2024) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2024.1462293 · Cited by 22
“This family controls the expression of genes involved in glycolysis, pH regulation, wound healing, angiogenesis and other pro-tumorigenic processes, such as ECM remodeling (Kierans and Taylor, 2021; Lee et al., 2021; Khouzam et al., 2022).”
BackgroundThangwong, P., Tocharus, C., & Tocharus, J. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-04914-5 · Cited by 19
Unraveling the Triad: Hypoxia, Oxidative Stress and Inflammation in Neurodegenerative Disorders
Dakal, T. C., Choudhary, K., Tiwari, I., Yadav, V., Maurya, P. K., & Sharma, N. K. (2024) · Neuroscience · doi:10.1016/j.neuroscience.2024.06.021 · Cited by 21
The potent role of Src kinase-regulating glucose metabolism in cancer
Shao, W., Liu, L., Zheng, F., Ma, Y., & Zhang, J. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115333 · Cited by 15
Schildhauer, P., Selke, P., Staege, M. S., Harder, A., Scheller, C., Strauß, C., Horstkorte, R., Scheer, M., & Leisz, S. (2023) · Cells · doi:10.3390/cells12232758 · Cited by 13
Associations between HIFs and tumor immune checkpoints: mechanism and therapy
Liu, J., Jiang, Y., Chen, L., Qian, Z., & Zhang, Y. (2024) · Discover Oncology · doi:10.1007/s12672-023-00836-7 · Cited by 13
“Notably, Belzutifan (MK-6482), a specific small molecule inhibitor that targets the TF HIF-2, was shown to shrink tumors and stop tumor growth in over 90% of VHL patients in a 3-year research [150].”
BackgroundAngiogenesis in heterotopic ossification: From mechanisms to clinical significance
Li, S., Ran, R.-Y., Chen, J., Liu, M., Dang, Y.-M., & Lin, H. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122779 · Cited by 13
Aparicio-Fernandez, L., Antoran, A., Areitio, M., Rodriguez-Erenaga, O., Martin–Souto, L., Buldain, I., Márquez, J., Benedicto, A., Arteta, B., Pellón, A., et al. (2024) · Microbes and Infection · doi:10.1016/j.micinf.2024.105305 · Cited by 12
Advances in the role of GPX3 in ovarian cancer (Review)
Geng, D., Zhou, Y., & Wang, M. (2024) · International Journal of Oncology · doi:10.3892/ijo.2024.5619 · Cited by 13
“GPX3 can suppress the expression of HIF‑1 α by regulating ROS, affecting tumor cell energy metabolism, and inhibiting the growth of melanoma cells (51).”
BackgroundLiang, Z., He, H., Zhang, B., Kai, Z., & Zong, L. (2024) · Drug Development Research · doi:10.1002/ddr.22168 · Cited by 18
“In addition, upregulated HIF ‐ 1 α can promote fatty acid metabolism, maintain cellular energy demand, and reduce intracellular lipid accumulation by activating pathway pathways such as PPARs in a hypoxic environment (Lee et al., 2021).”
BackgroundZhang, Z., Wang, D., Xu, R., Li, X., Wang, Z., & Zhang, Y. (2024) · Biomolecules · doi:10.3390/biom14121592 · Cited by 16
“Thus, HIF-1 α not only directly participates in calcium metabolism regulation but also enhances cellular adaptability to hypoxic environments through other metabolic pathways [25].”
InfluentialChu, X., Wang, Z., Wang, W., Liu, W., Cao, Y., & Feng, L. (2023) · BMC Pulmonary Medicine · doi:10.1186/s12890-023-02468-7 · Cited by 12
“In addition, increased expression of HIF-1α is a key feature of hypoxic environment, which mediates the transcription of genes related to oxygen transfer and hypoxia metabolic adaptation, and plays an essential role in tumor proliferation, metabolism, angiogenesis, metastasis, and differentiation [53].”
BackgroundThe tumor microenvironment: adding pieces to the puzzle
Aguilar‐Cázares, D., Perez-Medina, M., Benito-Lopez, J. J., Galicia-Velasco, M., Meneses-Flores, M., Camarena, Á., & López-González, J. S. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1731338 · Cited by 16
Role of Hydrogen Sulfide and Hypoxia in Hepatic Angiogenesis of Portal Hypertension
Yang, H., Tan, M., Gao, Z.-Q., Wang, S., Lyu, L., & Ding, H. (2023) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2022.00217 · Cited by 17
Olejarz, W., & Basak, G. W. (2023) · Cancers · doi:10.3390/cancers15245765 · Cited by 14
“It has been shown that the AICD mechanism is key to improve the anti-tumor effect of CAR-T cells, whereas AICD resistance is associated with a reduced surface expression of CD95L upon restimulation [162,165–167].”
BackgroundDeng, Z., Li, B., Wang, W., Xia, W., Zhang, L., Chen, L., & Jin, W. (2024) · European journal of medical research · doi:10.1186/s40001-024-02050-9 · Cited by 12
“Another study has shown that ABT737, an inhibitor of Bcl2, decreases glucose uptake and lactate secretion in SKOV3 cells by downregulating glucose uptake-related protein expression through the Sirt3– HIF1α axis, thereby inhibiting ovarian cancer cell growth [24].”
BackgroundHIF1A/PCDH7 axis mediates fatty acid synthesis and metabolism to inhibit lung adenocarcinoma anoikis
Yang, X., Zhang, Q., Wei, L., & Liu, K. (2024) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.70001 · Cited by 13
Targeting ncRNAs to overcome metabolic reprogramming‑mediated drug resistance in cancer (Review)
Li, J., Li, Y., Fu, L., Chen, H., Du, F., Wang, Z., Zhang, Y., Huang, Y. Y., Miao, J., & Xiao, Y. (2025) · International Journal of Oncology · doi:10.3892/ijo.2025.5741 · Cited by 16
“HIF‑1 serves as a crucial regulator of cancer cell responses to hypoxia and facilitates metabolic switching, while HIF‑1 α is an important subtype (55).”
Vitamin D: What role in obesity-related cancer?
Martinez, P., & Grant, W. B. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.03.007 · Cited by 13
Research on the oncogenic role of the house-keeping gene GAPDH in human tumors
Shen, C., Li, W., & Wang, Y. (2023) · Translational Cancer Research · doi:10.21037/tcr-22-1972 · Cited by 12
“By activating HIF-1, the expression of enzymes involved in glycolysis, such as GAPDH, could be enhanced by p-AKT in cancer cells of the colon, kidney and liver (22-24).”
BackgroundLi, X., Huang, Y., Du, Y., Song, M., Wang, L., Li, H., Zhao, Y.-Q., Li, C., Yan, H., Shang, P., et al. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.149772 · Cited by 15
Wang, Q., Ying, X., Huang, Q., Wang, Z., & Duan, S. (2024) · Journal of Molecular Medicine · doi:10.1007/s00109-024-02458-0 · Cited by 14
“1) [3]. tsRNA tsRNA, formed through the enzymatic cleavage of pre-tRNA or mature tRNA [4], can be classified into two categories: tRF and tiRNA, each with distinct molecular sizes and physiological roles (Fig.”
Lobato, S., Salomón-Soto, V. M., Espinosa-Méndez, C. M., Herrera-Moreno, M. N., García-Solano, B., Pérez-González, E., Comba-Marcó-del-Pont, F., Montesano-Villamil, M., Mora-Ramírez, M. A., Mancilla-Simbro, C., et al. (2024) · Biomolecules · doi:10.3390/biom14121607 · Cited by 15
“These genes include those involved in angiogenesis, glycolysis, cell survival, and apoptosis [86,87].”
Recent Update of Natural Compounds as HIF-1α Inhibitors in Colorectal Carcinoma
Pandey, P., Lakhanpal, S., Mahmood, D., Baldaniya, L. H., Kang, H. N., Hwang, S., Kang, S., Choi, M. C., Moon, S., Pandey, S., et al. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s511406 · Cited by 14
“33,34 These findings indicate that HIF-1α enhances cell survival under low-oxygen conditions by reorganizing the cellular metabolic pathways.”
Fructose Metabolism in Cancer: Molecular Mechanisms and Therapeutic Implications
Chen, X., Yang, M., Wang, L., Tu, J., & Yuan, X. (2025) · International Journal of Medical Sciences · doi:10.7150/ijms.108549 · Cited by 14
“Interestingly, if HIF-1α is inhibited, hypoxic cancer cells engage compensatory pathways (Myc, PI3K-Akt, AMPK) to sustain glycolysis and fructose utilization (27).”
Jackson, T. K., & Rhode, C. (2024) · Aquaculture · doi:10.1016/j.aquaculture.2024.740786 · Cited by 12
HIF-1α and BMAL1 in bone regeneration: crosstalk between hypoxia response and circadian rhythm
Weng, Y., Xiong, J., Zhao, Q., & Tan, Z. (2026) · Bone Research · doi:10.1038/s41413-026-00506-8 · Cited by 16
Magar, A. G., Morya, V. K., & Noh, K.-C. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26157642 · Cited by 10
Protein homeostasis in the aged and diseased heart
Mainali, N., Ayyadevara, S., Ganne, A., Reis, R. J. S., & Mehta, J. L. (2023) · The Journal of Cardiovascular Aging · doi:10.20517/jca.2023.4 · Cited by 17
Synthesis and applications of metal organic frameworks in photodynamic therapy
Songca, S. P. (2024) · Journal of Photochemistry and Photobiology · doi:10.1016/j.jpap.2024.100245 · Cited by 9
Xiong, L., & Cheng, J. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1519592 · Cited by 14
“Recent research has also shown that melanoma cells grown in hypoxic conditions were found to be more resistant to chemotherapy, which was linked to an increased reliance on lipid synthesis and storage (53).”
Lu, B., Zhao, Q., Cai, Z., Qian, S., Mao, J., Zhang, L., Mao, X., Sun, X., Cui, W., & Zhang, Y. (2023) · Small · doi:10.1002/smll.202309060 · Cited by 12
Liang, K., Xu, L., Ta, Y., Wang, R., Ma, S., Xiao, C., Zhang, X., Gao, Y., & Li, M. (2025) · Fitoterapia · doi:10.1016/j.fitote.2025.106721 · Cited by 9
Li, J., Huang, Y., Li, J., Shi, M., Xiao, Y., Du, F., & Hu, G. (2026) · Molecular Cancer · doi:10.1186/s12943-026-02578-w · Cited by 13
“Under hypoxia, hypoxia-inducible factor 1-alpha (HIF-1α) is upregulated and mediates metabolic reprogramming in cancer cells [166].”
Saquib, M., Agnihotri, P., Sarkar, A., Malik, S., Mann, S., Chakraborty, D., Joshi, L., Malhotra, R., & Biswas, S. (2024) · Non-Coding RNA · doi:10.3390/ncrna10020022 · Cited by 11
“It is known that HIF1 α regulates many proteins that are involved in carbohydrate metabolism, invasion, angiogenesis, cell proliferation, and apoptosis pathways [28].”
BackgroundYing, M., & Hu, X. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.10.005 · Cited by 7
The anti-tumour role of ketogenic diet based on energy metabolism
Wu, J., Sun, X., Luo, H., Luo, X., & Sun, S. (2025) · Clinical Nutrition · doi:10.1016/j.clnu.2025.06.006 · Cited by 8
Han, Y., Ji, B., Leng, Y., & Xie, C. (2024) · Medicine · doi:10.1097/md.0000000000038349 · Cited by 6
Xie, H., Xiao, X., Yi, X., et al. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16050619 · Cited by 5
“…fi c cytotoxicity of MIL-101/ACF@CCM nanoparticles, various drugs were co-incubated with tumor cells in vitro, and the CCK8 kit was employed to measure drug toxicity. the inhibition of HIF-1 α expression was believed to ameliorate the hypoxic conditions within the tumor microenvironment [36].”
MethodTedeschi, B. B. B., Henrique, T., Vila, A. P. S., Rodrigues, G. H., Kawasaki‐Oyama, R. S., Pavarino, É. C., Morais, P. D. J., Possebon, V. S., Serafim, V., Castanhole-Nunes, M. M. U., et al. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118024 · Cited by 6
Zheng, T., Sun, C., Yun, C., Wang, H., & Liu, X. (2025) · Cancers · doi:10.3390/cancers17172787 · Cited by 7
Liang, J., Bai, Y., & Zhao, H. (2025) · Balkan Medical Journal · doi:10.4274/balkanmedj.galenos.2025.2025-7-262 · Cited by 5
Salemi, R., Sergi, V., Basile, M. S., Bravaccini, S., Frittitta, L., Graziano, A. C. E., Filippello, A., Malaguarnera, R., & Francesco, E. M. D. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06970-w · Cited by 8
“Interestingly, obese patients exhibit over-expression of the active form of the transcription factor hypoxia-inducible factor 1 alpha (HIF-1α), similar to tumor tissues [101, 102].”
Debruyne, C., Hodge, L., Hokamp, K., Ershova, A. S., Kröger, C., & Salcedo, S. P. (2026) · PLoS Pathogens · doi:10.1371/journal.ppat.1013265 · Cited by 5
Wang, H., Yan, L., Zhu, Y., et al. (2023) · Human Pathology · doi:10.1016/j.humpath.2023.09.002 · Cited by 5
Yuan, X., Huang, H., Yu, C., Tang, Z., & Li, Y. (2024) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-024-03024-8 · Cited by 5
“The HIF-1 transcription factor is overexpressed in various human cancers and plays a key role in driving tumor growth, invasion, and metastasis (Lee et al. 2021).”
Exploring the Link Between Noncoding RNAs and Glycolysis in Colorectal Cancer
Xu, L., Shen, Y., Zhang, C., Shi, T., & Sheng, X. (2025) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.70443 · Cited by 8
Mohammed, M. A., Soffar, A. A., Yousef, A. I., Salama, M., Ibrahim, F. A. R., El-Sewedy, T., & Elmetwalli, A. (2025) · Functional & Integrative Genomics · doi:10.1007/s10142-025-01663-5 · Cited by 5
“HIF1A plays a central role in adapting cancer cells to low-oxygen conditions by promot - ing glycolytic metabolism (Lee et al. 2021).”
Anwar, N., Malik, M. N. H., Atif, M., Alanzi, A. R., Alharbi, H. A., Younis, W., Abbas, M., & Solre, G. F. B. (2025) · Food Science & Nutrition · doi:10.1002/fsn3.71108 · Cited by 4
“One of the most notable findings was the significant downregulation of HIF1A and VEGF, both of which play essential roles in angiogenesis and tumor adaptation to hypoxic conditions (Lee et al. 2021; Li et al. 2022; Paredes et al. 2021; Shah et al. 2021).”
Cheng, K., Zhao, H., He, K., Xia, X., Wang, Y., Wang, S., & Li, W. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1748824 · Cited by 7
“This pathway is implicated in neuroinflammation, mitochondrial function, and neurogenesis, and is closely related to stress adaptation and metabolic regulation (Sharma et al., 2023; Lee et al., 2021).”
Wen, P., Li, H., Liu, L., Liu, X., Xu, Z., & Dong, J. (2024) · Technology in Cancer Research & Treatment · doi:10.1177/15330338241257490 · Cited by 5
“7,8 Under hypoxic conditions, upregulated HIF1 α expression in GSCs activates Wnt/ β -catenin signaling pathways, which induces GSCs differentiation into perivascular cells, causing internal vascularization of the tumor and antagonizing the effectiveness of anti-angiogenic drugs, and which can also…”
BackgroundDu, M., Xia, Y., Sun, J., Meng, Y., Wang, L., Yan, S., & Zhang, Q. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.139090 · Cited by 5
Carbonic anhydrase IX-targeted SMDCs for cancer precision treatment
Zhang, H., Feng, K., Li, G., Chen, W., Shao, Y., Ding, J., Zheng, M., Yuan, K., Sun, X., & Yang, P. (2025) · Chinese Chemical Letters · doi:10.1016/j.cclet.2025.111047 · Cited by 6
Akasha, R., Enrera, J. A., Fatima, S., Hegazy, A. M., Hussein, W., Nawaz, M., Alshammari, M. D., Almuntashiri, S., Albadari, N. G., Break, M. K. B., et al. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04018-w · Cited by 6
“Additionally, the plasticity of mitochondrial metabolism allows cancer cells to adapt to hypoxia, where hypoxia-inducible factor 1-alpha (HIF-1α) drives a metabolic shift toward OXPHOS and glycolysis to sustain tumor growth (Lee et al. 2021).”
Li, M., Wang, T., Guan, X., Yu, Z., Han, X., Qu, X.-H., Chen, Z.-P., Wang, X., & Wang, X. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-00964-z · Cited by 5
“AMPK has been reported to be associated with tumorigenesis and tumor metabolism by modulating the expression and function of various factors, including HIF-1 α 17 , mTOR 18 , c-Myc 19 and SIRT1 20 .”
Kim, Y. H. B., Choi, T.-R., Jo, S.-H., Song, W.-S., Kim, T., Kim, M.-G., Baek, J.-H., Kwon, S.-Y., Choi, B.-G., Seo, S. W., et al. (2025) · iScience · doi:10.1016/j.isci.2025.111890 · Cited by 7
“57 This metabolic modulation aligns with the observed changes in adipocytes treated with L. reuteri and provides evidence supporting the activation of HIF-1 signaling (Figure 5B).”
Minchenko, О. H., Abramchuk, A. I., Khikhlo, Y. P., Sliusar, M. Y., Halkin, O. V., Luzina, O. Y., Danilovsryi, S. V., Viletska, Y. M., & Minchenko, D. O. (2025) · Endocrine Regulations · doi:10.2478/enr-2025-0007 · Cited by 5
“…not only to chemotherapy, but also to the toxic effects of hypoxia through genome reprogramming including HIF-dependent and HIF-independent mechanisms (Minchenko and Caro 2000; Minchenko et al. 1994, 2005, 2019; Denko 2008; Sun and Denko 2014; Semenza 2017; Lee et al. 2021; Sliusar et al. 2023).”
Li, H., Zhijie-Zhang, Yangyang, Xiaohan-Yu, Jinmao-Li, Cui, H., Li, P., & Chen, B. (2025) · Cardiovascular Therapeutics · doi:10.1155/cdr/5632985 · Cited by 4
LncRNAs in hypoxic microenvironment; insight in their impact in cancer biology
Kuriakose, B. B., Hjazi, A., Saleh, R. O., Bishoyi, A. K., Jyothi, S. R., Almalki, S. G., Sridevi, G., Chaudhary, K., Zwamel, A. H., & Matchonov, O. (2025) · Functional & Integrative Genomics · doi:10.1007/s10142-025-01635-9 · Cited by 3
“Proline hydroxylase domain (PHD) proteins, Von Hippel–Lindau (VHL), and p300 are protein-coding genes that are known to influence the hypoxia/HIF-1α axis at the post-transcriptional level (Korbecki et al. 2021; Lee et al. 2021; Semenza 2003).”
Elian, V., Popovici, V., Nicolescu, M. I., Nicolescu, A. M., Aurelian, S. M., & Ozon, E. A. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47110929 · Cited by 4
“HIF pathways coordinate cellular responses to hypoxia and metabolic stress, playing substantial roles in both diabetic complications and cancer progression [99,132] (Table 4).”
Du, Z., Wang, Y., Wei, X., Zong, Y., & Dai, L. (2025) · Letters in Drug Design & Discovery · doi:10.1016/j.lddd.2025.100174 · Cited by 3
Kanwal, B., Pounraj, S., Hanif, R., & Kovačević, Ž. (2026) · Cancers · doi:10.3390/cancers18020294 · Cited by 3
“HIF—1 α -independent metabolic re-programming in the context of cancer-stroma crosstalk has been previously reported, supporting the role of the TME in shaping cancer cell metabolism [47].”
Golinska, M. A., Stubbs, M., Harris, A. L., Boros, L. G., Madhu, B., McIntyre, D. J. O., & Griffiths, J. R. (2022) · Cells · doi:10.3390/cells11223595 · Cited by 5
Self-citationRole of natural secondary metabolites as HIF-1 inhibitors in cancer therapy
Mishra, P. S., Mishra, R., Patil, V. M., & Dewangan, S. (2024) · Medicinal Chemistry Research · doi:10.1007/s00044-024-03219-x · Cited by 4
“A different investigation found that when combined with dihydroartemisinin, dictamnine causes cell cycle arrest and increases apoptotic cell death [58].”
Son, T. H., Kim, S., Shin, H.-L., Kim, D., Kim, H. G., Choi, Y., & Choi, S. (2024) · Molecules · doi:10.3390/molecules29102218 · Cited by 3
“The regulation of this metabolic switch can be influenced by various pathways, one of which involves the hypoxia-inducible factor-1 α (HIF-1 α ), known for its role in promoting the upregulation of glycolytic enzymes [36].”
BackgroundMetabolic regulation of the tumour and its microenvironment: The role of Epstein–Barr virus
Lee, S., Khoo, A. S. B., Griffiths, J. R., & Lazim, N. M. (2024) · International Journal of Cancer · doi:10.1002/ijc.35192 · Cited by 7
“67 In addition, cancer cells employ various acid extrusion mechanisms such as carbonic anhydrases, Na + -HCO 3 (cid”
Self-citationHu, X., Guo, X., Dongxu, W., Yue, J., Zhang, J., & Wang, B. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e39292 · Cited by 3
“Under normoxic conditions, HIF-1 α undergoes hydroxylation at proline residues 402 and 564, which triggers its degradation via the ubiquitin-proteasome pathway [34].”
Metadata
- Authors
- Lee, S.-H., Golinska, M., & Griffiths, J. R.
- Affiliations
- Hospital Sultanah Bahiyah (MY)
- University of Cambridge (GB)
- Corresponding author
- Lee, Shen-Han
- Venue
- Cells
- Publisher
- MDPI AG
- Published
- 2021-09-09
- Volume
- 10
- Issue
- 9
- Pages
- 2371
- ISSN
- 2073-4409 (ISSN-L)
- PMC
- PMC8472468
- OpenAlex
- W3197266090
- Cited by
- 169
- References
- 219
- Citations by year
- 2026: 31 · 2025: 48 · 2024: 50 · 2023: 22 · 2022: 18
- FWCI
- 2.71
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cells (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Apollo (University of Cambridge) (submittedVersion, cc-by)
- Apollo
- Apollo (cc-by)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- HIF-1, hypoxia, cancer metabolism, metabolic adaptation, HIF-1 inhibitors, drug resistance, ARNT, HIF-2, creatine metabolism, glucose metabolism, glutamine metabolism, lipid metabolism, epigenetic regulation, post-translational modification, c-Myc, PI3K/Akt, 2-hydroxyglutarate, AMPK, tumor hypoxia
- MeSH terms
- Adaptation, Physiological, Animals, Humans, Neoplasms, Signal Transduction, Cell Hypoxia, Hypoxia-Inducible Factor 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.